Medical Instruments & Supplies , Healthcare , After action review
Impact Of Insider Trading Signal On Lucyd, Inc: A Retrospective Analysis - One Day After The Signal
- Acquired: Non-Derivative
On January 7, 2026, an insider trading signal was released for PharmaCyte Biotech, Inc. after Joshua Silverman, Director and Interim CEO, purchased stock worth $53,340. This triggered significant price movements, with the stock peaking at $0.98 from an initial $0.83, closing at $0.8975 on January 9. The market's positive reaction signaled increased confidence in PharmaCyte Biotech, reflecting the influence of insider activities on stock performance.
Pages total: 7